Oxford brings rare venture capital-backed ABS

Pharma,
By Jennifer Kang
22 Jan 2020

Venture capital firm Oxford Finance is issuing a $312.8m securitization backed by loans made to life sciences and healthcare companies, the largest deal from the issuer and its fastest return to market since issuing its previous deal.

Oxford is a specialty finance company that makes "venture debt" investment in life sciences and healthcare companies with a focus on biotech, pharmaceuticals and medical devices, according to a pre-sale report from Kroll Bond Rating Agency. Since its beginning in 2002, Oxford has originated $5bn loans to more ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Or sign up for a trial to gain full access to the entire site for a limited period.

Free Trial

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.